Search Results - non-novel

60 Results Sort By:
Gut-specific serotonin transporter inhibitors for treatment of constipation
Value Proposition·       Potent inhibition of serotonin transporter (SERT) in GI system·       Luminally and or/peripherally-restricted SERT inhibitors·       Result in enhanced action of serotonin in stimulation of GI motility·       Spares the body of systemic and CNS effectsUnmet NeedConstipation-predominant IBS involves reduced gastrointestinal...
Published: 3/13/2025   |   Inventor(s): Pankaj Pasricha, James Barrow, Qian Li, Pablo de Leon, Yifang Huang
Keywords(s): Antagonists/Inhibitors, Biomarker, Disease Indication, Gastrointestinal Disorders, Mechanism-of-action Biomarker, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Gastroenterology
Discovery of Small Molecule Inhibitors of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative Diseases
Unmet NeedIn the brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increased activity and expression of this enzyme has been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Inhibition of human nSMase2 may preserve neuronal function...
Published: 3/13/2025   |   Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Radim Nencka, Michal Sala, Hubert Hrebabecky, Norman Haughey
Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, Assay, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease
Biopolymer Encapsulation Increases the Bioavailability and Efficacy of D-PDMP in Interfering with Atherosclerosis and Cardiac Hypertrophy in apoE-/- Transgenic Mice
INVENTION NOVELTYA novel glycolipid inhibitor anti-atherosclerosis drug compound able to enhancegastro-intestinal absorption and residence time to reduce and ameliorateeffects of arteriosclerosis VALUE PROPOSITIONDespite great success of statins (cholesterol reducing agents), little is known aboutother molecules such as glycolipids that also rise with...
Published: 3/13/2025   |   Inventor(s): Subroto Chatterjee
Keywords(s): Antagonists/Inhibitors, Cardiovascular Diseases, Disease Indication, Drug Delivery Vehicle, Non-novel, Off-the-shelf, Polymers, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities
Farnesylation of PARIS Prevents Dopaminergic Neurodegeneration in Models of Parkinson’s Disease
Unmet Need: Parkinson's disease (PD) is an incurable progressive neurodegenerative disease. It is characterized clinically by motor dysfunction that is due to the preferential loss of dopaminergic neurons in the brain. Current treatment strategies for PD are mainly limited to the management of the motor symptoms with drugs such as L-DOPA or dopamine...
Published: 3/13/2025   |   Inventor(s): Ted Dawson, Valina Dawson, Joo-Ho Shin, Yunjong Lee, Areum Jo
Keywords(s): Agonists/Promoters, CNS and Neurological Disorders, Disease Indication, Non-novel, Off-the-shelf, Parkinson's Disease, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Parkinson's Disease
Tonabersat as a Neuroprotective Compound for Amyotrophic Lateral Sclerosis
Unmet NeedAmytrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons, and results in muscle atrophy and loss of motor control. ALS affects approximately 17,000 people in the United States and 450,000 worldwide at any given time, and the average life expectancy from diagnosis to mortality is between 2-5 years....
Published: 3/14/2025   |   Inventor(s): Nicholas Maragakis
Keywords(s): Amyotrophic Lateral Sclerosis, Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis
M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)
Unmet NeedGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incrementally improved, survival rates remains dismal. Only...
Published: 3/14/2025   |   Inventor(s): Ru Chih Huang, Jong ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai
Keywords(s): Agonists/Promoters, Brain Cancer, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Glioblastoma, Glioma, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Brain Cancer
Pharmacological Intervention of the Arachidonic Acid Pathway to Cure Amyotrophic Lateral Sclerosis
Unmet NeedAmyotrophic Lateral Sclerosis (ALS) affects as many as 30,000 people in the United States alone, with 5,000 new cases diagnosed every year. ALS is a fatal neuromuscular disease that is characterized by a progressive degeneration of the motor nerve cells and spinal cord. There are only two drugs approved by FDA for the treatment of ALS, and...
Published: 3/14/2025   |   Inventor(s): Gabsang Lee, Hyungjin Eoh, Hojae Lee, Thomas Lloyd, Nicholas Maragakis
Keywords(s): Amyotrophic Lateral Sclerosis, CNS and Neurological Disorders, Disease Indication, Natural compounds, Non-novel, Predicted Novelty, Target, Therapeutic Matter, Therapeutics
Category(s): Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Repurposed Drugs
Identification of Novel Coumestan Derivatives as Pks13 Inhibitors against Mycobacterium Tuberculosis
Unmet NeedTuberculosis (TB) is an infectious disease caused by the bacteria Mycobacterium tuberculosis (Mtb), which typically impacts the lungs. In 2016, there were 10.4 million new cases of TB and 1.7 million deaths worldwide, with approximately one-fourth of the world’s population infected. As a result, TB is one of the leading infectious disease...
Published: 3/14/2025   |   Inventor(s): William Bishai, Shichun Lun, Li-Fang Yu, Shu-Huan Wang, Fan Yang, Jie Tang, Hendra Gunosewoyo, Ashlee Earl, Abigail Manson, Wei Zhang
Keywords(s): Antagonists/Inhibitors, Disease Indication, Infectious Diseases, Myobacterium Tuberculosis, Natural compounds, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Tuberculosis (TB)
Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases > Tuberculosis (TB)
Low Dose Adjuvant Epigenetic Modifiers Inhibit Cancer Lung Metastases through Disruption of the Myeloid Environment in Pre-metastatic Niches
Unmet NeedCancer recurrence, even following complete surgical resection, remains a large unmet clinical problem. In non-small cell lung cancer (NSCLC) patients, recurrence following surgery remains 30-70%, and the five-year survival rate remains 23% with over 140,000 deaths occurring each year. Recurrence post-surgery can be driven by a number of factors,...
Published: 3/14/2025   |   Inventor(s): Malcolm Brock, Zhihao Lu
Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Chemotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations > Oncology > Lung Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules
Locoregional Chemotherapy for Liver Cancers
Unmet NeedOver 800,000 people are diagnosed with liver cancer annually. As the leading cause of cancer death worldwide, liver cancer accounts for more than 700,000 deaths annually. Recently, Johns Hopkins researchers have developed new chemotherapeutic drugs to treat liver cancer that demonstrate higher efficacy than the current standard of care for...
Published: 3/14/2025   |   Inventor(s): Florin Selaru, Ling Li
Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Drug Delivery Mechanism, Liver Cancer, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Liver Cancer
1 2 3 4 5 6 
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum